| Ident. | Authors (with country if any) | Title |
|---|
| 000181 (2017) |
Federica Grosso ; Nicola Steele ; Silvia Novello ; Anna K. Nowak ; Sanjay Popat ; Laurent Greillier ; Thomas John ; Natasha B. Leighl ; Martin Reck ; Paul Taylor ; David Planchard ; Jens Benn S Rensen ; Mark A. Socinski ; Ute Von Wangenheim ; Arsène Bienvenu Loembé ; José Barrueco ; Nassim Morsli ; Giorgio Scagliotti | Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. |
| 000D98 (2017) |
Ming Jang Chua ; Megan S J. Arnold ; Weijun Xu ; Julien Lancelot ; Suzanne Lamotte ; Gerald F. Sp Th ; Eric Prina ; Raymond J. Pierce ; David P. Fairlie ; Tina S. Skinner-Adams ; Katherine T. Andrews | Effect of clinically approved HDAC inhibitors on Plasmodium, Leishmania and Schistosoma parasite growth. |
| 001243 (2017) |
Elizabeth M. Swisher ; Kevin K. Lin ; Amit M. Oza ; Clare L. Scott ; Heidi Giordano ; James Sun ; Gottfried E. Konecny ; Robert L. Coleman ; Anna V. Tinker ; David M. O'Malley ; Rebecca S. Kristeleit ; Ling Ma ; Katherine M. Bell-Mcguinn ; James D. Brenton ; Janiel M. Cragun ; Ana Oaknin ; Isabelle Ray-Coquard ; Maria I. Harrell ; Elaina Mann ; Scott H. Kaufmann ; Anne Floquet ; Alexandra Leary ; Thomas C. Harding ; Sandra Goble ; Lara Maloney ; Jeff Isaacson ; Andrew R. Allen ; Lindsey Rolfe ; Roman Yelensky ; Mitch Raponi ; Iain A. Mcneish | Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. |
| 001892 (2016) |
Paolo A. Ascierto ; Grant A. Mcarthur ; Brigitte Dréno ; Victoria Atkinson ; Gabrielle Liszkay ; Anna Maria Di Giacomo ; Mario Mandalà ; Lev Demidov ; Daniil Stroyakovskiy ; Luc Thomas ; Luis De La Cruz-Merino ; Caroline Dutriaux ; Claus Garbe ; Yibing Yan ; Matthew Wongchenko ; Ilsung Chang ; Jessie J. Hsu ; Daniel O. Koralek ; Isabelle Rooney ; Antoni Ribas ; James Larkin | Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. |
| 002483 (2016) |
Peter Reichardt ; George D. Demetri ; Hans Gelderblom ; Piotr Rutkowski ; Seock-Ah Im ; Sudeep Gupta ; Yoon-Koo Kang ; Patrick Schöffski ; Jochen Schuette ; Denis Soulières ; Jean-Yves Blay ; David Goldstein ; Kolette Fly ; Xin Huang ; Massimo Corsaro ; Maria Jose Lechuga ; Jean-Francois Martini ; Michael C. Heinrich | Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. |
| 002830 (2015) |
Jean Jacques Grob ; Mayur M. Amonkar ; Boguslawa Karaszewska ; Jacob Schachter ; Reinhard Dummer ; Andrzej Mackiewicz ; Daniil Stroyakovskiy ; Kamil Drucis ; Florent Grange ; Vanna Chiarion-Sileni ; Piotr Rutkowski ; Mikhail Lichinitser ; Evgeny Levchenko ; Pascal Wolter ; Axel Hauschild ; Georgina V. Long ; Paul Nathan ; Antoni Ribas ; Keith Flaherty ; Peng Sun ; Jeffrey J. Legos ; Diane Opatt Mcdowell ; Bijoyesh Mookerjee ; Dirk Schadendorf ; Caroline Robert | Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. |
| 002902 (2015) |
Michael B. Atkins ; Gwenaelle Gravis ; Kazimierz Drosik ; Tomasz Demkow ; Piotr Tomczak ; Shirley S. Wong ; M Dror Michaelson ; Toni K. Choueiri ; Benjamin Wu ; Lynn Navale ; Douglas Warner ; Alain Ravaud | Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. |
| 002991 (2015) |
Tamera Corte ; Francesco Bonella ; Bruno Crestani ; Maurits G. Demedts ; Luca Richeldi ; Carl Coeck ; Katy Pelling ; Manuel Quaresma ; Joseph A. Lasky | Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. |
| 002B66 (2015) |
Mitchell S. Stark ; Vanessa F. Bonazzi ; Glen M. Boyle ; Jane M. Palmer ; Judith Symmons ; Catherine M. Lanagan ; Christopher W. Schmidt ; Adrian C. Herington ; Robert Ballotti ; Pamela M. Pollock ; Nicholas K. Hayward | miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. |
| 002D06 (2015) |
M E Gore ; C. Szczylik ; C. Porta ; S. Bracarda ; G A Bjarnason ; S. Oudard ; S-H Lee ; J. Haanen ; D. Castellano ; E. Vrdoljak ; P. Schöffski ; P. Mainwaring ; R E Hawkins ; L. Crin ; T M Kim ; G. Carteni ; W E E. Eberhardt ; K. Zhang ; K. Fly ; E. Matczak ; M J Lechuga ; S. Hariharan ; R. Bukowski | Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. |
| 002D63 (2015) |
Andrew J. Muir ; Fred Poordad ; Jacob Lalezari ; Gregory Everson ; Gregory J. Dore ; Robert Herring ; Aasim Sheikh ; Paul Kwo ; Christophe Hézode ; Paul J. Pockros ; Albert Tran ; Joseph Yozviak ; Nancy Reau ; Alnoor Ramji ; Katherine Stuart ; Alexander J. Thompson ; John Vierling ; Bradley Freilich ; James Cooper ; Wayne Ghesquiere ; Rong Yang ; Fiona Mcphee ; Eric A. Hughes ; E Scott Swenson ; Philip D. Yin | Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. |
| 002D97 (2015) |
Fred Poordad ; William Sievert ; Lindsay Mollison ; Michael Bennett ; Edmund Tse ; Norbert Br U ; James Levin ; Thomas Sepe ; Samuel S. Lee ; Peter Angus ; Brian Conway ; Stanislas Pol ; Nathalie Boyer ; Jean-Pierre Bronowicki ; Ira Jacobson ; Andrew J. Muir ; K Rajender Reddy ; Edward Tam ; Grisell Ortiz-Lasanta ; Victor De Lédinghen ; Mark Sulkowski ; Navdeep Boparai ; Fiona Mcphee ; Eric Hughes ; E Scott Swenson ; Philip D. Yin | Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. |
| 003296 (2014) |
James Larkin ; Paolo A. Ascierto ; Brigitte Dréno ; Victoria Atkinson ; Gabriella Liszkay ; Michele Maio ; Mario Mandalà ; Lev Demidov ; Daniil Stroyakovskiy ; Luc Thomas ; Luis De La Cruz-Merino ; Caroline Dutriaux ; Claus Garbe ; Mika A. Sovak ; Ilsung Chang ; Nicholas Choong ; Stephen P. Hack ; Grant A. Mcarthur ; Antoni Ribas | Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. |
| 003510 (2014) |
Robert J. Motzer ; Carlos H. Barrios ; Tae Min Kim ; Silvia Falcon ; Thomas Cosgriff ; W Graydon Harker ; Vichien Srimuninnimit ; Ken Pittman ; Roberto Sabbatini ; Sun Young Rha ; Thomas W. Flaig ; Ray Page ; Sevil Bavbek ; J Thaddeus Beck ; Poulam Patel ; Foon-Yiu Cheung ; Sunil Yadav ; Edward M. Schiff ; Xufang Wang ; Julie Niolat ; Dalila Sellami ; Oezlem Anak ; Jennifer J. Knox | Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. |
| 003741 (2014) |
B. Escudier ; M D Michaelson ; R J Motzer ; T E Hutson ; J I Clark ; H Y Lim ; E. Porfiri ; P. Zalewski ; G. Kannourakis ; M. Staehler ; J. Tarazi ; B. Rosbrook ; L. Cisar ; S. Hariharan ; S. Kim ; B I Rini | Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. |
| 003887 (2014) |
Grant A. Mcarthur ; Paul B. Chapman ; Caroline Robert ; James Larkin ; John B. Haanen ; Reinhard Dummer ; Antoni Ribas ; David Hogg ; Omid Hamid ; Paolo A. Ascierto ; Claus Garbe ; Alessandro Testori ; Michele Maio ; Paul Lorigan ; Celeste Lebbé ; Thomas Jouary ; Dirk Schadendorf ; Stephen J. O'Day ; John M. Kirkwood ; Alexander M. Eggermont ; Brigitte Dréno ; Jeffrey A. Sosman ; Keith T. Flaherty ; Ming Yin ; Ivor Caro ; Suzanne Cheng ; Kerstin Trunzer ; Axel Hauschild | Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. |
| 003896 (2014) |
Thomas E. Hutson ; Bernard Escudier ; Emilio Esteban ; Georg A. Bjarnason ; Ho Yeong Lim ; Kenneth B. Pittman ; Peggy Senico ; Andreas Niethammer ; Dongrui Ray Lu ; Subramanian Hariharan ; Robert J. Motzer | Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. |
